Micro Medical Solutions announced today that it completed enrollment in a U.S. pivotal clinical study of its MicroStent system.
Wilmington, Massachusetts-based Micro Medical set up its study to evaluate MicroStent’s safety and effectiveness. The study pits the stent against the current standard of care, percutaneous transluminal angioplasty (PTA).
MicroStent, a vascular stent, was designed to achieve and maintain tibioperoneal arterial patency. Micro Medical aims for it to improve blood flow and wound-healing for below-the-knee (BTK) amputation reduction in patients with critical limb ischemia (CLI) resulting from progressive peripheral artery disease (PAD). MicroStent currently holds CE mark approval but remains investigational in the U.S.
STAND, a trial led by Dr. Robert E. Beasley of Palm Vascular Centers in Miami Beach, Florida, enrolled its final patient earlier this month.
Micro Medical VP of Clinical Affairs Rita Jacob said the compan…